My Top 5 Stocks to Buy in Early 2026

Core Viewpoint - The article highlights five top stocks to consider for investment in early 2026, emphasizing their strong earnings potential and growth opportunities in various sectors. Group 1: Amazon - Amazon is positioned as a strong investment due to its leadership in e-commerce and cloud computing, with a market cap of $2.6 trillion and a gross margin of 50.05% [5][3] - The company is leveraging artificial intelligence to enhance its e-commerce efficiency and AWS has an annual revenue run rate exceeding $132 billion [5][3] - The stock is considered a safe bet with a current price of $240.95, reflecting a 3.38% increase [4][3] Group 2: Eli Lilly - Eli Lilly is a leader in the weight loss drug market, particularly with its products tirzepatide (Zepbound and Mounjaro), contributing to significant sales growth [6][8] - The company has a market cap of $1 trillion and a gross margin of 83.03%, with a current stock price of $1,064.04, up 2.16% [7][6] - The weight loss drug market is projected to reach nearly $100 billion by the end of the decade, indicating substantial growth potential for Lilly [9] Group 3: Chewy - Chewy operates in the pet e-commerce space, expanding into veterinary services, which broadens its revenue opportunities [10][12] - The company has achieved profitability and 84% of its sales come from its Autoship service, providing predictable revenue [12][11] - Chewy's current market cap is $13 billion, with a gross margin of 28.58% and a stock price of $32.16, reflecting a slight increase of 0.05% [11][10] Group 4: Apple - Apple has underperformed compared to the S&P 500 but is now focusing on AI features, which may attract investors looking for growth [14][15] - The company has a market cap of $3.9 trillion and a gross margin of 46.91%, with a current stock price of $262.36, down 1.83% [15][14] - Apple's services segment is a significant growth area, consistently reporting record revenues [16] Group 5: Moderna - Moderna is identified as a recovery story, facing challenges due to declining vaccine sales but has a promising pipeline of late-stage candidates [18][19] - The company aims to expand its seasonal vaccine offerings from three to six products by 2028 and is working towards cash breakeven [19][20] - Moderna has a market cap of $14 billion, a gross margin of 38.93%, and a current stock price of $35.66, reflecting a 10.85% increase [19][18]